Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03494114 · ClinicalTrials.gov registry record · Phase 1

Imaging Activated Macrophages in the Lungs

A Phase 1 study, sponsored by Vanderbilt University Medical Center.

Terminated
Registry status
Phase 1
Development phase
13
Enrollment target

NCT03494114 is a Phase 1 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 13 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03494114, a Phase 1 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.

TERMINATED
Registry status
Phase 1
Development phase
13 participants
Enrollment target

Study Summary

To test whether folate-based positron emission tomography (PET) imaging using 68Ga-EC2115 can differentiate chronic obstructive pulmonary disease (COPD) patients from control subjects and determine whether the PET signal correlates with measurements of inflammation and disease severity.

Interventions

  • DRUG Ga-EC2115

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2018-11-29
Est. Completion 2021-01-13
Phase Phase 1

What the Registry Record Tells You About NCT03494114

The ClinicalTrials.gov registry entry for NCT03494114 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Ga-EC2115 is the first listed.

NCT03494114 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03494114 about?

NCT03494114 is a clinical study titled "Imaging Activated Macrophages in the Lungs". To test whether folate-based positron emission tomography (PET) imaging using 68Ga-EC2115 can differentiate chronic obstructive pulmonary disease (COPD) patients from control subjects and determine whether the PET signal correlates with measurements of inflammation and disease severity.

What is the current status of trial NCT03494114?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2018-11-29. Estimated completion is 2021-01-13.

What interventions are being tested in trial NCT03494114?

The interventions under investigation include: Ga-EC2115 (DRUG).

Who is sponsoring clinical trial NCT03494114?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.